KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) Revenue (2016 - 2025)

Neogenomics' Revenue history spans 16 years, with the latest figure at $190.2 million for Q4 2025.

  • For Q4 2025, Revenue rose 10.56% year-over-year to $190.2 million; the TTM value through Dec 2025 reached $727.3 million, up 10.11%, while the annual FY2025 figure was $727.3 million, 10.11% up from the prior year.
  • Revenue reached $190.2 million in Q4 2025 per NEO's latest filing, up from $187.8 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $190.2 million in Q4 2025 to a low of $115.5 million in Q1 2021.
  • Average Revenue over 5 years is $148.7 million, with a median of $149.4 million recorded in 2023.
  • The largest YoY upside for Revenue was 39.95% in 2021 against a maximum downside of 3.27% in 2021.
  • A 5-year view of Revenue shows it stood at $125.7 million in 2021, then grew by 10.32% to $138.7 million in 2022, then increased by 12.15% to $155.6 million in 2023, then rose by 10.57% to $172.0 million in 2024, then rose by 10.56% to $190.2 million in 2025.
  • Per Business Quant, the three most recent readings for NEO's Revenue are $190.2 million (Q4 2025), $187.8 million (Q3 2025), and $181.3 million (Q2 2025).